ライフサイエンスコーパス: hyperlipidemia

1 c abnormalities (diabetes, hypertension, and hyperlipidemia).

2 confidence interval, 1.05-1.85 per decade of hyperlipidemia).

3 y complications (diabetes, hypertension, and hyperlipidemia).

4 HE is not significantly associated with hyperlipidemia.

5 rowth of breast cancer using mouse models of hyperlipidemia.

6 n type 9 (PCSK9) has been developed to treat hyperlipidemia.

7 e effect on unilateral VI when combined with hyperlipidemia.

8 syndrome with proteinuria, weight gain, and hyperlipidemia.

9 sened metrics of diabetes, hypertension, and hyperlipidemia.

10 rol transport genes in the liver to suppress hyperlipidemia.

11 olic disorders such as obesity, diabetes and hyperlipidemia.

12 ed thrombosis specifically in the setting of hyperlipidemia.

13 ies that have been extensively used to treat hyperlipidemia.

14 emia, kidney donor risk index, and recipient hyperlipidemia.

15 valent HRP prevalence as older patients with hyperlipidemia.

16 f lipid droplets in hepatocytes and systemic hyperlipidemia.

17 on of remnant lipoproteins, and postprandial hyperlipidemia.

18 responding lipid levels and risk of incident hyperlipidemia.

19 isk factors for lipids increase and incident hyperlipidemia.

20 ght constitute a novel approach for treating hyperlipidemia.

21 in increased hepatic de novo lipogenesis and hyperlipidemia.

22 lerate thrombosis in mice in the settings of hyperlipidemia.

23 or the treatment of hypercholesterolemia and hyperlipidemia.

24 osis, and atherosclerosis in the settings of hyperlipidemia.

25 patients with chronic periodontitis (CP) and hyperlipidemia.

26 ecreased atherosclerotic plaque formation in hyperlipidemia.

27 1.64; 95% CI, 1.02-2.68) but not obesity or hyperlipidemia.

28 ditions, such as diabetes, hypertension, and hyperlipidemia.

29 inuation of medications for hypertension and hyperlipidemia.

30 cluding hyperglycemia, hyperinsulinemia, and hyperlipidemia.

31 tolerance, weight gain, hepatosteatosis, and hyperlipidemia.

32 Zealand White (NZW) rabbits on diet-induced hyperlipidemia.

33 animal models of acute and high-fat-induced hyperlipidemia.

34 tor class B type 1 may account for alcoholic hyperlipidemia.

35 M2 patients and patients with statin-treated hyperlipidemia.

36 thnicity, and residency to 788 controls with hyperlipidemia.

37 ature to exacerbate atherogenesis upon acute hyperlipidemia.

38 BACE1 and Abeta accompany hyperglycemia and hyperlipidemia.

39 nditions such as diabetes, hypertension, and hyperlipidemia.

40 It is mainly used in familial hyperlipidemia.

41 wledge to propose a molecular target against hyperlipidemia.

42 abetes mellitus, ischaemic heart disease and hyperlipidemia.

43 CCD36 and accelerated thrombosis observed in hyperlipidemia.

44 s of treatment of hypertension (0-2 points), hyperlipidemia (0-2 points), and atrial fibrillation (0-

45 For hyperlipidemia (0.14) and angina (0.10), slight agreemen

46 r hypertension, 0.97 (95% CI: 0.88-1.08) for hyperlipidemia, 1.01 (95% CI: 0.89-1.15) for diabetes me

47 .6%]; hypertension, 3.2% [CI, 2.2% to 4.2%]; hyperlipidemia, 1.5% [CI, 0.6% to 2.5%]).

48 smoking, diabetes mellitus, hypertension, or hyperlipidemia), 1036 subjects had 1 to 2 RF, and 1253 h

49 hotic; hazard ratio=1.63, 95% CI=0.98-2.70), hyperlipidemia (12.9% for clozapine vs. 8.5% for standar

50 scular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common

51 ion (31.4%, 39.3%, and 76.2%, respectively), hyperlipidemia (29.2%, 22.1%, and 49.6%), and endocrine

52 , hypertension (47.1% vs 45.4%; P = .73), or hyperlipidemia (52.3% vs 63.4%; P = .45).

53 ange, 53-71], 87% men, 85% hypertension, 51% hyperlipidemia, 56% smokers).

54 y, was less than 10%, with the exceptions of hyperlipidemia (6.1% vs 11.2%), hypertension (9.8% vs 18

55 rted rates of medication discontinuation for hyperlipidemia (60.7% vs 43.2%, P < .001), diabetes (ins

56 the most prevalent risk factor for NAION was hyperlipidemia (62.9%); for diabetic patients, NAION ris

57 r diabetes mellitus (70.9% versus 81.3%) and hyperlipidemia (66.2% versus 78.4%) and less likely to a

58 an 90% of patients; agreement was lowest for hyperlipidemia (68%; kappa = 0.36) and arthritis (66%; k

59 pe 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertens

60 hypertension; 5) coronary heart disease; 6) hyperlipidemia; 7) alcohol abuse; 8) tobacco use disorde

61 le, white (87.2%), had hypertension (83.7%), hyperlipidemia (72.1%), diabetes mellitus (31.6%), and c

62 risk factors included hypertension (83.3%), hyperlipidemia (83.3%), and small cup-to-disc ratio (63.

63 We stratified patients with hyperlipidemia according to the risk categories outlined

64 imen) evaluated LDL apheresis in nonfamilial hyperlipidemia acute coronary syndrome patients treated

65 regression with LDL apheresis in nonfamilial hyperlipidemia acute coronary syndrome patients treated

66 d liver accumulation of glycogen and develop hyperlipidemia, adiposity as well as insulin resistance

67 Hyperlipidemia (adjusted odds ratio [AOR], 1.3; 95% conf

68 Conclusions: Before hyperlipidemia, aging elevates IL-6 and impairs mitochon

69 mellitus [DM], obesity, hypertension [HTN], hyperlipidemia, alcohol use, renal impairment, chronic k

70 her with previous reports demonstrating that hyperlipidemia also impairs lung innate defense, these r

71 e younger and female but less likely to have hyperlipidemia, although other cardiovascular risk facto

72 ins) are widely prescribed for patients with hyperlipidemia and are generally well tolerated.

73 It is highly upregulated in hyperlipidemia and atherosclerosis in a CX3CR1-independe

74 expression of microRNA-30c (miR-30c) reduced hyperlipidemia and atherosclerosis in mice without causi

75 ther a miR-30c mimic can be used to mitigate hyperlipidemia and atherosclerosis without inducing stea

76 prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis.

77 ge- and sex-matched groups: 18 patients with hyperlipidemia and CP (HLp), 18 periodontally healthy pa

78 besity-associated metabolic disorders (e.g., hyperlipidemia and diabetes) and periodontitis has been

79 ic Ces1/Ces1g in Apoe (-/-) mice resulted in hyperlipidemia and exacerbated Western diet-induced athe

80 Interaction term between hyperlipidemia and gender or obesity was significant for

81 to have diabetes mellitus, hypertension, and hyperlipidemia and have higher discharge blood pressures

82 ked HFD-induced obesity, insulin resistance, hyperlipidemia and hepatic steatosis.

83 Therefore, both hyperlipidemia and hyperleptinemia contribute to male ma

84 estimated national control of hyperglycemia, hyperlipidemia and hypertension (especially for young me

85 with diabetes had controlled hyperglycemia, hyperlipidemia and hypertension, respectively.

86 In this respect, although obesity promotes hyperlipidemia and hypothalamic injury, MC4R agonists ar

87 His medical history was significant for hyperlipidemia and hypothyroidism.

88 ed atherosclerosis through the generation of hyperlipidemia and increased adiposity.

89 peroxidation, accumulating in circulation in hyperlipidemia and inducing platelet activation by promo

90 The irisin lacking mice had hyperlipidemia and insulin resistance, reduced HDL-chole

91 severe side effects including hyperglycemia, hyperlipidemia and obesity.

92 s IL-6 expression, is upregulated by LPS and hyperlipidemia and patients with familial hypercholester

93 harmful oxidative status in association with hyperlipidemia and periodontitis.

94 cells might serve as a possible link between hyperlipidemia and psoriasis.

95 y reported, fenugreek attenuated HFD-induced hyperlipidemia and stabilized glucose tolerance without

96 . We investigated the independent effects of hyperlipidemia and statin exposure on mortality, hepatic

97 ly hypermethylated in Mvarphis isolated from hyperlipidemia and T2DM ischemic muscles compared with c

98 lammatory, proangiogenic M2-Mvarphi genes in hyperlipidemia and T2DM ischemic muscles.

99 nflammatory and proangiogenic M2-Mvarphis in hyperlipidemia and T2DM ischemic muscles.

100 Compared with the controls, hyperlipidemia and T2DM mice showed impaired perfusion r

101 It interacted with diabetes mellitus, hyperlipidemia and white matter hyperintensities to pred

102 pathways linking diet-induced changes (e.g., hyperlipidemia) and the ensuing inflammation have remain

103 , hypertension, metabolic syndrome, smoking, hyperlipidemia, and a sedentary lifestyle are the major

104 and selected effects on glucose regulation, hyperlipidemia, and adipose pathology; but may not be as

105 nd leader in the field of diabetes, obesity, hyperlipidemia, and atherosclerosis.

106 physical activity, energy intake, diabetes, hyperlipidemia, and BMI.

107 diabetes mellitus (p = 0.004), hypertension, hyperlipidemia, and chronic kidney disease (all p < 0.00

108 r risk factors, including diabetes mellitus, hyperlipidemia, and cigarette smoking to cases.

109 rior to conception caused maternal and fetal hyperlipidemia, and consequently larger fetuses.

110 , geographic region, hypertension, diabetes, hyperlipidemia, and coronary heart disease, the hazard r

111 the treatment of hypertension/heart failure, hyperlipidemia, and diabetes mellitus in a dataset of 9,

112 Age, hyperlipidemia, and diabetes mellitus were three signifi

113 were diagnosed or treated for hypertension, hyperlipidemia, and diabetes mellitus, respectively.

114 other comorbid conditions (ie, hypertension, hyperlipidemia, and diabetes), use of controller asthma

115 28% to 31% of US patients with hypertension, hyperlipidemia, and diabetes, may be improved by electro

116 barrier and is associated with proteinuria, hyperlipidemia, and edema.

117 mice develop severe lipodystrophy, diabetes, hyperlipidemia, and fatty liver disease within the first

118 lation to effects on metrics of body weight, hyperlipidemia, and glucose tolerance.

119 ely to be male, have a smoking history, have hyperlipidemia, and have HF with reduced ejection fracti

120 rformed, and data on age, sex, hypertension, hyperlipidemia, and hemoglobin A1c were collected.

121 ate lipogenesis, resulting in hyperglycemia, hyperlipidemia, and hepatic steatosis.

122 Diabetes, hyperlipidemia, and hypertension are modifiable risk fac

123 Factors such as high BMI, diabetes, hyperlipidemia, and hypertension at first diagnosis of s

124 e achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current

125 lic risk factors, including body mass index, hyperlipidemia, and hypertension, were not associated wi

126 dy showed that diet-induced hepatosteatosis, hyperlipidemia, and insulin resistance can be completely

127 metabolic syndrome, including hyperglycemia, hyperlipidemia, and insulin resistance.

128 and fatty acids to prevent hepatosteatosis, hyperlipidemia, and insulin resistance.

129 carcinoma, comorbidity index, hypertension, hyperlipidemia, and obesity by Cox's proportional hazard

130 Diabetes, hypertension, hyperlipidemia, and obesity were all found to be risk fa

131 ns (such as hypertension, diabetes mellitus, hyperlipidemia, and obesity).

132 rs (such as smoking, diabetes, hypertension, hyperlipidemia, and overweight) and encouraging healthy

133 nges are associated with higher body weight, hyperlipidemia, and severe insulin and glucose intoleran

134 emographics, cohort, hypertension, diabetes, hyperlipidemia, and tobacco use, risk differences compar

135 the primary outcome, incident hypertension, hyperlipidemia, and type 2 diabetes.

136 elated risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation,

137 etermine whether simvastatin consumption and hyperlipidemia are associated with a worse periodontal c

138 as been established, the effects of moderate hyperlipidemia are less clear.

139 ane biophysical changes due to infection and hyperlipidemia are one of the key mechanisms by which C.

140 Serum hyperlipidemias are common human diseases that could be

141 tory of smoking, hypertension, diabetes, and hyperlipidemia, as well as personal and family history o

142 on of miR-155-5p expression in beta-cells by hyperlipidemia-associated endotoxemia improves the adapt

143 In this study, we demonstrate that hyperlipidemia-associated endotoxemia upregulates miR-15

144 mine the role of CD1-autoreactive T cells in hyperlipidemia-associated inflammatory diseases.

145 ysm, Down syndrome, sleep apnea, depression, hyperlipidemia, astigmatism, and myopia.

146 rotein (MTP) inhibitors is limited to severe hyperlipidemias because of associated hepatosteatosis an

147 hronic diseases (diabetes, hypertension, and hyperlipidemia) between 2011 and 2013.

148 hronic diseases (diabetes, hypertension, and hyperlipidemia) between 2011 and 2013.

149 ins are promising compounds for ameliorating hyperlipidemia but scarce information exists about sapog

150 ession was induced in response to injury and hyperlipidemia but was absent at later time points, and

151 She had no history of hyperlipidemia, but multiple blood samples were grossly

152 ertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had receiv

153 ntima formation in the comorbid condition of hyperlipidemia by potentiating SMC proliferation and mig

154 nd the prothrombotic state in the setting of hyperlipidemia by sensing a wide range of endogenous lip

155 /- 6 [standard deviation]) with asymptomatic hyperlipidemia by using a 320-detector row scanner (Aqui

156 s the role of cafeteria diet-induced obesity/hyperlipidemia (CAF) on alveolar bone loss (ABL) in rats

157 ups: control, periodontitis (PERIO), obesity/hyperlipidemia (CAF), and obesity/hyperlipidemia plus pe

158 ss proteinuria, hypoalbuminaemia, edema, and hyperlipidemia, can be clinically divided into steroid-s

159 mmation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery dis

160 e diabetes [prediabetes or type 2 diabetes], hyperlipidemia, cardiovascular events, and chronic kidne

161 a medical history notable for hypertension, hyperlipidemia, cigarette smoking, type II diabetes mell

162 a medical history notable for hypertension, hyperlipidemia, cigarette smoking, type II diabetes mell

163 ble analyses adjusting for Elixhauser index, hyperlipidemia, confounding drugs, and surgery type, odd

164 pendent of age, sex, diabetes, hypertension, hyperlipidemia, current smoking, left anterior descendin

165 tory included prostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

166 The presence of diabetes, hypertension, or hyperlipidemia defined metabolically abnormal patients.

167 On the other hand, hyperlipidemia, depression, and DM (uncomplicated and co

168 Our study found that patients with hyperlipidemia, depression, or DM were less likely to ha

169 Resident participation; hypertension and hyperlipidemia detection, treatment, and control; smokin

170 ent indications (hypertension/heart failure, hyperlipidemia, diabetes mellitus), but were attenuated

171 therapy, including measures of hypertension, hyperlipidemia, diabetes, bone disease, and hematologic

172 location and residential urbanization level, hyperlipidemia, diabetes, coronary heart disease, migrai

173 nce of atrial septal aneurysm, hypertension, hyperlipidemia, diabetes, hypercoagulability, or hypermo

174 At baseline, women had lower rates of hyperlipidemia, diabetes, smoking, and renal disease but

175 Many young adults with moderate hyperlipidemia do not meet statin treatment criteria und

176 increases hepatic triglyceride synthesis and hyperlipidemia due to increased fatty acid esterificatio

177 tients with psoriasis (n=105), patients with hyperlipidemia eligible for statin therapy under Nationa

178 ne if vascular aging before the induction of hyperlipidemia enhances atherogenesis.

179 Elderly patients and those with hyperlipidemia experienced fewer typical symptoms than t

180 icantly elevated among adults with prolonged hyperlipidemia exposure by 55 years of age: 4.4% for tho

181 ngth, disc area, hypertension, diabetes, and hyperlipidemia, eyes of Indians were observed to have 3.

182 rs (PPARs), has been generally used to treat hyperlipidemia for decades.

183 es (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional status, and patient satisfac

184 Hyperlipidemia further reduced mitochondrial function an

185 ions for 6 chronic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid

186 92,868) reveal connections with proteinuria, hyperlipidemia, gout, and hypertension.

187 ween 8-OHdG and MDA was also observed in the hyperlipidemia group.

188 tributed to lipid levels change and incident hyperlipidemia >8.1-year follow-up among 6428 individual

189 ascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-t

190 While the prothrombotic risk of severe hyperlipidemia has been established, the effects of mode

191 Hyperlipidemia has been extensively studied in the conte

192 ith better long-term %WL, while preoperative hyperlipidemia, higher body mass index, and older age we

193 HLp), 18 periodontally healthy patients with hyperlipidemia (HLh), 19 systemically healthy individual

194 0.001), diabetes (HR: 2.766; P < 0.001), and hyperlipidemia (HR: 1.641; P < 0.001).

195 the most common drugs for old patients with hyperlipidemia, hypercholesterolemia and atherosclerotic

196 Nod2 (-/-) HFD mice developed hyperlipidemia, hyperglycemia, glucose intolerance, incr

197 5 and HR = 2.70, 95% CI 1.81-4.03), although hyperlipidemia, hypertension, and COPD did not.

198 as a result of metabolic sequelae including hyperlipidemia, hypertension, and diabetes.

199 6-2011 evaluated MU in relation to diabetes, hyperlipidemia, hypertension, chronic obstructive pulmon

200 tory seem to be risk factors for MU, but not hyperlipidemia, hypertension, or COPD.

201 ted morbidity and mortality in patients with hyperlipidemia, hypertension, or type 2 diabetes.

202 syndrome, valvular disease, carotid disease, hyperlipidemia, hypertension, retinal vasculitis or infl

203 roke, atrial fibrillation, coronary disease, hyperlipidemia, hypertension, sleep apnea, diabetes mell

204 We triggered acute hyperlipidemia in aged and young mice by inducing liver-

205 in the liver leads to hepatic steatosis and hyperlipidemia in animals under prolonged fasting.

206 anced perspective for screening and managing hyperlipidemia in children.

207 (-/-) dams developed glucose intolerance and hyperlipidemia in late pregnancy.

208 y identify the influence of hyperglycemia or hyperlipidemia in producing specific cellular changes, s

209 but only the 7-methyl-9cUAB30 caused severe hyperlipidemia in rats.

210 t association between cumulative exposure to hyperlipidemia in young adulthood and subsequent CHD ris

211 Cumulative exposure to hyperlipidemia in young adulthood increases the subseque

212 ted metabolic dysregulation characterized by hyperlipidemia, increased adiposity, and insulin resista

213 inhibitors led to a significant decrease in hyperlipidemia-induced IL-1beta and IL-18 production, lo

214 Furthermore, ISR inhibitors suppress hyperlipidemia-induced inflammasome activation and infla

215 Such diets lead to obesity, hyperlipidemia, insulin resistance, and steatosis that m

216 delian randomization, we found evidence that hyperlipidemia is a causal risk factor for ALS and local

217 Hyperlipidemia is a highly heritable risk factor for cor

218 Hyperlipidemia is a major risk factor for cardiovascular

219 Atherosclerosis, for which hyperlipidemia is a major risk factor, is the leading ca

220 Hyperlipidemia is a risk factor for dementia, and chroni

221 Hyperlipidemia is a well-established risk factor for car

222 In addition to hyperglycemia, hyperlipidemia is also closely related with diabetic ret

223 of atherosclerosis independently of chronic hyperlipidemia is not known.

224 Although hyperlipidemia is traditionally considered a risk factor

225 f miR-155-5p in the islet stress response to hyperlipidemia is unclear.

226 aired in diabetes and suggests that treating hyperlipidemia is vital for proper cardiac signaling and

227 , and comorbidities (diabetes, hypertension, hyperlipidemia, ischemic heart disease, and glaucoma).

228 history of hypertension, diabetes mellitus, hyperlipidemia, ischemic heart disease, stroke, total ch

229 ulin and adiponectin, severe lipoatrophy and hyperlipidemia lead to lethality.

230 smooth muscle cells of young mice exposed to hyperlipidemia led to increased aortic Parkin and IL-6 l

231 In concert with hyperlipidemia, maladaptive immune system activities can

232 gement of comorbidities such as diabetes and hyperlipidemia may help to limit late vascular complicat

233 ioenergetics or reducing inflammation before hyperlipidemia may reduce age-related atherosclerosis.

234 Among obesity and hyperlipidemia measures no factors were related to perio

235 score, inherited aortopathies, hypertension, hyperlipidemia, medications, aortic regurgitation, and r

236 increases in prevalence of obesity, smoking, hyperlipidemia, migraine, and gestational hypertension.

237 n LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia; NCT02833844).

238 athero-prone regions of arteries, and, in a hyperlipidemia model, reduced atherosclerotic plaque siz

239 Obesity and hyperlipidemia modulate the host response to challenges

240 g antihypertensive medications), and 60% had hyperlipidemia, nearly half of whom were receiving lipid

241 the association between duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol

242 es, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, an

243 cells in the human body under conditions of hyperlipidemia/obesity, OA-treated cells gain or reduce

244 duce lipoprotein particles, exacerbating the hyperlipidemia of fasting and postprandial states.

245 hen cultured in the presence of FFA to mimic hyperlipidemia of obesity.

246 Preoperative hyperlipidemia, older age, and higher body mass index we

247 nt improvement in the prediction of incident hyperlipidemia on top of traditional risk factors includ

248 ion (P = .023), hypertension (P = .021), and hyperlipidemia or obesity (P = .0004) were more common i

249 sis showed diabetes mellitus (P = .0001) and hyperlipidemia or obesity (P = .0142) were more common i

250 ues from donors either with diabetes or with hyperlipidemia or obesity reduced the failure rate from

251 donors either with diabetes mellitus or with hyperlipidemia or obesity reduced the failure rate.

252 especially with longer disease duration) and hyperlipidemia or obesity were associated with higher fa

253 4.0% +/- 3.4%) with no significant impact of hyperlipidemia or smoking.

254 gical disorder (OR 1.25; 95% CI: 1.18-1.32), hyperlipidemia (OR 1.21; 95% CI: 1.14-1.28), smoking his

255 titis (OR = 4.55), hypertension (OR = 3.02), hyperlipidemia (OR = 2.87), increasing age (OR = 2.24),

256 Obesity (odds ratio [OR]: 2.13), hyperlipidemia (OR, 4.13), hypertension (OR, 3.67), high

257 g, P=.003), hypertension (OR=10.93, P=.002), hyperlipidemia (OR=4.36, P=.04) and diabetes family hist

258 nd CVD risk factors (diabetes, hypertension, hyperlipidemia) or subclinical CVD measures (coronary ar

259 least one comorbidity, such as hypertension, hyperlipidemia, or coronary artery disease.

260 x, education level, oral hygiene habits, and hyperlipidemia (P = 0.049).

261 demia than in the diet-treated patients with hyperlipidemia (P = 0.05).

262 nificant strongest associations for incident hyperlipidemia (P range from 1.20x10(-3) to 4.67x10(-16)

263 at lower traditional risk than patients with hyperlipidemia, patients with psoriasis had increased NC

264 ), obesity/hyperlipidemia (CAF), and obesity/hyperlipidemia plus periodontitis (CAF+PERIO).

265 New data suggest that diet, hyperlipidemia, pollutants, commensal microbes, and path

266 coronary artery disease, diabetes type 2 and hyperlipidemia presented with no symptoms of mitral valv

267 models of atherosclerosis, normalization of hyperlipidemia promotes macrophage emigration and regres

268 be two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/)(-)/LDLR(-/)(-) and Rag1(-/)(-)/

269 exhibited apparent phenotypes of obesity and hyperlipidemia regardless of exposure to casein injectio

270 reases over time and the incidence of future hyperlipidemia remains largely unknown.

271 ients, the simvastatin-treated patients with hyperlipidemia showed a mean reduction of 0.8 mm (95% co

272 The presence of obesity and hyperlipidemia significantly increased ABL in the CAF+PE

273 s (obesity, diabetes mellitus, hypertension, hyperlipidemia, smoking) with >/=1 risk factors in 58% o

274 users (n = 1,272; 33.9%) had higher rates of hyperlipidemia, smoking, a history of percutaneous coron

275 ents' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, and renal impairment.

276 ion exists that controls for factors such as hyperlipidemia, smoking, medication, and disease stage,

277 glucagon and T3 actions synergize to correct hyperlipidemia, steatohepatitis, atherosclerosis, glucos

278 This study demonstrates that oxLDL and hyperlipidemia stimulate the generation of NOX2-derived

279 a mouse model of combined hyperglycemia and hyperlipidemia (streptozotocin-induced diabetic apolipop

280 ensates for the antiproliferative effects of hyperlipidemia, such that atherosclerosis was exacerbate

281 her in the simvastatin-treated patients with hyperlipidemia than in the diet-treated patients with hy

282 was higher in the diet-treated patients with hyperlipidemia than in the normolipidemic controls (P =

283 continuation for diabetes, hypertension, and hyperlipidemia than LAGB.

284 potential anti-hypercholesterolemia and anti-hyperlipidemia therapies.

285 groups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); abs

286 may provide a novel strategy for obesity and hyperlipidemia treatment.

287 orbidities including diabetes, hypertension, hyperlipidemia, venous stasis, and sleep apnea.

288 lopment of atherosclerosis in the setting of hyperlipidemia via reduction of macrophage recruitment i

289 creening of persons with a family history of hyperlipidemia vs. general screening) in younger adults.

290 ongestational hypertension and diabetes; and hyperlipidemia were assessed semiannually for 5 years.

291 Midlife hypertension and hyperlipidemia were associated with 29% (prevalence rati

292 le older age, temporary housing, obesity and hyperlipidemia were associated with higher risk for bila

293 lacks only, whereas midlife hypertension and hyperlipidemia were associated with late-life ICAD in bo

294 ass index (summarized odds ratio = 1.27) and hyperlipidemia were the most consistent predictors of ou

295 A total of 394 patients with ECC and hyperlipidemia who received care at Mayo Clinic Rocheste

296 lowering trials enrolling 4300 patients with hyperlipidemia who were randomly assigned to receive 150

297 s for devising novel strategies to attenuate hyperlipidemia, with the potential for cardiovascular di

298 , insulin resistance, hepatic steatosis, and hyperlipidemia without changes in food intake, physical

299 n patients with coronary artery diseases and hyperlipidemia without effect on LDL level.

300 Overall, 85% of young adults with prolonged hyperlipidemia would not have been recommended for stati